pharmaphorum
JANUARY 3, 2024
The race for obesity drug assets is becoming more intense as pharmaceutical companies strive to develop effective treatments for weight loss. This article explores the efficacy, potential sales, and market trends in the field of obesity drugs.
Pharmacy Is Right For Me
JANUARY 3, 2024
“How can I make the biggest difference in the lives of others? How can I help the most people?” These questions often cross the minds of students as they navigate the labyrinth of career choices. Dr. Linda Gutierrez-Miller, one such student, embarked on a journey to answer these questions, ultimately choosing a career path that aligns with her goals of making a substantial impact and aiding a diverse range of individuals—clinical pharmacy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
JANUARY 4, 2024
A new study found that 16.1% of patients treated with nirmatrelvir-ritonavir (Paxlovid) reported long COVID symptoms, compared to 14% of untreated patients.
Pharmacy Times
JANUARY 4, 2024
Due to the observational nature of the study, the study authors said they cannot determine causal relationships between statins and cognitive decline for patients with Alzheimer disease.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
JANUARY 4, 2024
“I’m sorry, but I’m unable to take on new patients at this time.” I’ve said that line hundreds of times in the 15 years since I started my solo private practice in psychiatry. I feel terrible each time I say it. Someone on the other end of the phone is suffering and has taken the difficult step to call for help — probably multiple calls, given the longstanding shortage of psychiatrists — and yet I added to their hopelessness.
Fierce Pharma
JANUARY 2, 2024
On the heels of a major Paxlovid inventory write-off in the United States, many more doses of Pfizer's COVID-fighting antiviral are going to waste overseas. | At the end of November, more than 1.5 million courses of Pfizer’s Paxlovid had expired unused in European countries, analysts at Airfinity said in a new report. The total tally of expired doses in Europe is expected to hit 3.1 million by the end of next month, representing a value of $2.2 billion.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
JANUARY 4, 2024
The risk of poor cognitive performance was nearly double in participants who had the greatest number of sleep disturbances compared to the least.
STAT
JANUARY 3, 2024
First, a light starts to flash. Then a high-pitched siren starts to blare. Then come the sounds of nearby doors being flung open, and the frantic footsteps of doctors and nurses rushing toward a restroom at the end of a hallway. They’re in a hurry for good reason. These distress signals have a specific meaning: Somebody in the bathroom is overdosing.
Fierce Pharma
JANUARY 3, 2024
As the J.P. | As the J.P. Morgan Healthcare Conference rolled on in San Francisco, BioNTech, Alnylam and many other companies updated investors on their strategies heading into 2024.
Drug Topics
JANUARY 4, 2024
In response to a surge in cases of COVID-19, flu, and RSV, hospitals are reinstating mask guidelines to avoid adverse capacity outcomes and staffing shortages seen in prior years.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
JANUARY 3, 2024
Available data indicate that as much as 50% of all antibiotics prescribed for individuals may be either unnecessary or not administered in the most effective manner as recommended.
STAT
JANUARY 2, 2024
AUSTIN, Texas — Eleven years ago, local officials promised voters in the most liberal county in Texas that if they supported tens of millions of dollars in new taxes, they’d deliver a win-win scenario: Austin would get a new medical school, and poor people navigating the health care system in a state with the country’s worst uninsured rate would get more health care services.
Fierce Pharma
JANUARY 4, 2024
Use of Novo Nordisk and Eli Lilly’s popular diabetes and weight loss drugs come with warnings about a rare intestinal blockage condition called ileus, which can be life threatening. | Use of Novo Nordisk and Eli Lilly’s popular diabetes and weight loss drugs come with warnings about a rare intestinal blockage condition called ileus. Could cautions about more common side effects soon be added to the labels of popular treatments such as Novo’s Ozempic and Lilly’s Mounjaro?
Drug Topics
JANUARY 5, 2024
A model showed that if a vaccine coverage of 66% were achieved—similar to flu vaccination coverage—it could have a budget impact of $6.48 to $6.78 billion over the first RSV season.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
JANUARY 3, 2024
The study highlights the ongoing need for health care providers to recommend respiratory illness vaccinations to increase protection among nursing home residents during the peak season of infection.
STAT
JANUARY 3, 2024
Investment bank Goldman Sachs is jumping into the biotech world after raising $650 million to invest in privately held startups. The bank announced Wednesday that it has closed its first-ever life sciences fund, called West Street Life Sciences I. The plan is to invest the money in genetic medicine, cell therapies, immunotherapies, synthetic biology and artificial intelligence startups, as well as diagnostics and life science tools companies.
pharmaphorum
JANUARY 4, 2024
Amplifying the patient voice is essential for the success of clinical trials. Learn why it is crucial for patient engagement, recruitment, and overall trial success, and how it can address challenges such as transportation and financial barriers.
Drug Topics
JANUARY 4, 2024
Patients on a moderate carbohydrate diet increased their time in range by 4.7% and decreased their time above range by 5.9%.
Pharmacy Times
JANUARY 3, 2024
Liraglutide, a glucagon-like peptide 1 receptor agonist, has shown a clinically and significant reduction in glycated hemoglobin for those with type 2 diabetes.
STAT
JANUARY 2, 2024
For all the flack they get, the country’s four biggest pharmacy benefit managers reported a surprisingly tame average profit margin in the first three quarters of 2023: 4.5%, less than a third of their drugmaker peers. But don’t take their numbers as gospel, experts warned. “It’s really easy to move money around inside the books of a vertically integrated organization,” said Karen Van Nuys, a senior fellow at the USC Schaeffer Center for Health Policy and Econo
Fierce Pharma
JANUARY 5, 2024
Three days after the FDA included Novo Nordisk’s semaglutide treatments Ozempic and Wegovy on a list of medicines that it would monitor for side effects—one of them suicide ideation—a study of medi | Three days after the FDA included Novo Nordisk’s semaglutide treatments Ozempic and Wegovy on a list of medicines that it would monitor for side effects—one of them suicide ideation—a study of medical records of patients shows no link between use of the GLP-1 drugs and an increase in suicidal though
Drug Topics
JANUARY 5, 2024
The Starlyng-1 study showed that the treatment met its primary endpoint of a one-sided Cmin of >0.80; a one-sided Cmax of <1.25; and a two-sided Cavg of 0.80-1.40, with 90% confidence limits.
Pharmacy Times
JANUARY 2, 2024
The new understanding of immune cells could not only contribute to the development of lung disease treatments, but treatments for other organ systems as well.
STAT
JANUARY 3, 2024
Mapping the billions of cells that make up the brain is a task mammoth enough to keep hundreds of researchers across continents busy for years. But it’s just one of several ambitious projects the Allen Institute is helping tackle. The nonprofit research institute, based in Seattle, was founded in 2003 by Microsoft co-founder and philanthropist Paul Allen to go after big and basic scientific questions.
Fierce Healthcare
JANUARY 3, 2024
A “pivotal year for price transparency” closed out with most—but not all—of the healthcare industry publishing their data publicly and at a higher quality, price transparency data startup Turquoise | A state-of-the-industry report released Thursday found steady improvements in the number of organizations releasing price data, as well as the comprehensiveness and usability of those data.
Drug Topics
JANUARY 5, 2024
By importing drugs in bulk from Canada, Florida aims to relieve the financial strain faced by patients who struggle to afford necessary medications.
Pharmacy Times
JANUARY 5, 2024
In-hospital mortality and the Medicare Bundled Payments for Care Improvement (BPCI) model are not associated with changes in odds for Black individuals or female individuals.
STAT
JANUARY 3, 2024
Margery Quackenbush was attending a board meeting of the nonprofit where she served as executive director when she felt a sharp, stabbing pain in her chest. As the organization’s president yelled at a board member, Quackenbush — then age 69 — noticed her heart tightening and felt terrified. After that day more than 15 years ago, her cardiologist began a series of tests.
Fierce Pharma
JANUARY 2, 2024
AbbVie is entering 2024 with a foothold in the antibody-drug conjugate (ADC) field thanks to its late-2023 buyout of ImmunoGen worth more than $10 billion. | According to a recent securities filing, AbbVie only entered the ImmunoGen bidding war after other buyout interest led the ADC specialist to widen its pool of potential purchasers. When it came down to the final three players, AbbVie's offer blew the others out of the water.
pharmaphorum
JANUARY 3, 2024
The UK medicines regulator has launched its mutual recognition framework for authorising medicines in a move that it says will help to bring new drugs to patients in the UK more quickly.
Pharmacy Times
JANUARY 5, 2024
Although machine learning models demonstrate potential to improve early detection of Alzheimer disease, sample sizes that underrepresent ethnic and racial groups result in unfairness.
STAT
JANUARY 2, 2024
The first phone call came some time in late 1996. “Ed, I’d like to introduce myself. My name is Sid Wolfe of Public Citizen,” he said. “And I’ve got something for you.” He started out matter of fact, but spoke very quickly. To be honest, I can’t recall the subject anymore, but I do remember he peppered every sentence with lots of medical terminology.
Fierce Pharma
JANUARY 3, 2024
Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk and Eli Lilly—overwhelming the market wi | Booming demand for blood sugar-modulating diabetes and obesity drugs became the top trend in the biopharma industry in 2023, with two companies—Novo Nordisk and Eli Lilly—overwhelming the market with their dominance.
Fierce Healthcare
JANUARY 3, 2024
Hospitals and clinician groups are pushing back on federal regulators' proposal to enforce data blocking rules, arguing that the penalties are "excessive," "unfair" and will discourage participatio | Hospitals and medical groups are pushing back on federal regulators' proposal to enforce data blocking rules, arguing that the penalties are "excessive," "unfair" and will discourage participation in value-based care programs.
Expert insights. Personalized for you.
118 
Let's personalize your content